Patient-reported Outcomes and Health-related Quality of Life in Prostate Cancer Treated with a Single Fraction of High Dose Rate Brachytherapy Combined with Hypofractionated External Beam Radiotherapy

Choudhury, Ananya; Arthur, C.; Malik, Jahangeer; Mandall, Paula; Taylor, Cathy M.; Alam, Nooreen; Tran, Anna; Livsey, Jacqueline E; Elliott, Tony; Davidson, Susan E; Logue, John P; Wylie, James

doi:10.1016/j.clon.2014.06.012

Cited by 12 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EPIC scores revealed mainly urinary baseline symptoms and showed transient changes in both domains over time similarly to literature findings [21,22,25]. Apart from a posttreatment decline, we noted a transient drop in GI QoL at bRFS: biochemical relapse-free survival (Phoenix definition: PSA nadir þ2 ng/ ml); LRFS: local relapse-free survival; DMFS: distant metastasis-free survival; DFS: disease-free survival; CSS: cancer-specific survival; OS: overall survival.…”

Section: Discussionsupporting

confidence: 87%

“…The dominant urinary symptom was dysuria as 17% of the patient developed transitory or permanently alpha blocker dependence. A low Gr.3 stricture rate of 2.6% was observed, which compares favorably to published results of 3-12% [1][2][3][4][5][6]22,23]. Despite the lack of clear correlation between dose-volume, non-dosimetry factors and stricture incidence [23,24], we believe that MR-based definition of membranous urethra might improve dose delivery and eventually decrease toxicity.…”

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy

Lakosi

Antal

Pall³

et al. 2017

Acta Oncologica

View full text Add to dashboard Cite

View related articles View Crossmark data Citing articles: 2 View citing articles of six cases, whereas only two of seven differed among the other LR. Our material was not large enough to perform robust statistical analysis to look deeper into the relationship with time to recurrence and distant metastasis. In conclusion, the current outcome of a more detailed intrinsic subtype analysis does not seem to provide further insight into the reasons for the nature of the excess frequency of in-breast recurrences in younger low-risk patients.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Discussionsupporting

confidence: 79%

Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy

Lakosi

Antal

Pall³

et al. 2017

Acta Oncologica

View full text Add to dashboard Cite

show abstract

“…The primary objective was to evaluate the differences in HRQOL in the urinary domain between patients treated with LDRB and HDRB at 3 months using the Expanded Prostate Cancer Index Composite (EPIC)-26 short form 25 . The 3-month cut-off was chosen as the primary endpoint based on several studies revealing peak urinary symptoms at 3 to 6 months 26, 27, 28, 29, 30, 31, 32. The EPIC score is the most used HRQOL instrument; it has been validated in men with prostate cancer 33 and shown to be a robust tool with good psychometrics 34, 35, 36.…”

Section: Methodsmentioning

confidence: 99%

“…Studies evaluating QoL for patients treated with EBRT and HDRB were used as a surrogate for sample size calculation. Six studies investigating the effect of LDRB 26,29,32 and EBRT plus HDRB boost 27,30,31 on urinary function, using the urinary domain of the EPIC instrument as an outcome, were selected. Raw change scores from baseline were calculated and converted to effect sizes (d ), which were weighted using the study sample size and averaged by treatment modality (LDRB vs HDRB þ EBRT).…”

Section: Sample Sizementioning

confidence: 99%

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

Hathout

Mahmoud

Wang

et al. 2019

Advances in Radiation Oncology

View full text Add to dashboard Cite

PurposeTo compare health-related quality of life (HRQOL) of high-dose-rate brachytherapy (HDRB) versus low dose-rate brachytherapy (LDRB) for localized prostate cancer in a multi-institutional phase 2 randomized trial.Methods and MaterialsMen with favorable-risk prostate cancer were randomized between monotherapy brachytherapy with either Iodine-125 LDRB to 144 Gy or single-fraction Iridium-192 HDRB to 19 Gy. HRQOL and urinary toxicity were recorded at baseline and at 1, 3, 6, and 12 months using the Expanded Prostate Cancer Index Composite (EPIC)-26 scoring and the International Prostate Symptom Score (IPSS). Independent samples t test and mixed effects modeling were performed for continuous variables. Time to IPSS resolution, defined as return to its baseline score ±5 points, was calculated using Kaplan-Meier estimator curves with the log-rank test. A multiple-comparison adjusted P value of ≤.05 was considered significant.ResultsLDRB and HDRB were performed in 15 and 16 patients, respectively, for a total of 31 patients. At 3 months, patients treated with LDRB had a higher IPSS score (mean, 15.5 vs 6.0, respectively; P = .003) and lower EPIC urinary irritative score (mean, 69.2 vs 85.3, respectively; P = .037) compared with those who received HDRB. On repeated measures at 1, 3, 6, and 12 months, the IPSS (P = .003) and EPIC urinary irritative scores (P = .019) were significantly better in the HDR arm, translating into a lower urinary toxicity profile. There were no significant differences in the EPIC urinary incontinence, sexual, or bowel habit scores between the 2 groups at any measured time point. Time to IPSS resolution was significantly shorter in the HDRB group (mean, 2.0 months) compared with the LDRB group (mean, 6.0 months; P = .028).ConclusionsHDRB monotherapy is a promising modality associated with a lower urinary toxicity profile and higher HRQOL in the first 12 months compared with LDRB.

show abstract

“…76% for 24 months PRO data and 81% healthcare professional reported toxicity in prostate cancer patients. In comparison single centre studies in prostate cancer patients carried out up to two years following radiotherapy reported overall questionnaire completion rates of 50% [30], 85% in ProtecT [31], and 69% in CHHiP [32]. The REQUITE study also aimed at a low level of missing data, e.g.…”

Section: *5mentioning

confidence: 99%

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Seibold

Webb

Aguado-Barrera

et al. 2019

Radiotherapy and Oncology

View full text Add to dashboard Cite

Patient-reported Outcomes and Health-related Quality of Life in Prostate Cancer Treated with a Single Fraction of High Dose Rate Brachytherapy Combined with Hypofractionated External Beam Radiotherapy

Cited by 12 publications

References 17 publications

Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy

Clinical outcome in prostate cancer treated with magnetic resonance imaging-guided high-dose-rate brachytherapy combined with external beam radiotherapy

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer

REQUITE: A prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer

Contact Info

Product

Resources

About